September 18, 2020
A quadruple witching Friday which may also account for some higher than normal volumes in share trading and option alignments
Pre-open indications: 1 SELL <Biostage (BSTG)>
What I provide is an “intelligence daily” to ensure that shareholders are kept apprised based on a 24-hour surveillance of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!
My gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times!
September 15, 2020
A scorecard of 1 restatement and 1 acquisition of 35 covered companies
The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status"
September 18, 2020
Friday’s quadruple witching got a lot of fanfare yet, didn’t quite live up to its moniker as a volume disrupter; volume was orderly and a little heavy as the sector retuned to Wednesday’s pricing levels
The week’s “numbers” in review
An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector. I say today what others won't, so you can do what others can't.
Subscription is coming, my gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times!
September 15, 2020
A scorecard of 1 restatement and 1 acquisition of 35 covered companies The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status"
August 12, 2020
16,675 million shares were offered which included an additional 2,175 million underwiter option Goldman Sachs & Co. LLC, Cowen and Company, LLC, SVB Leerink LLC and Piper Sandler & Co. are acting as joint book-running managers for the proposed offering. ADVM is DOWN -$0.16 to $13.55 at closing
July 8, 2020
BLFS' underwriters' option included an additional 776,250 shares The gross proceeds from the offering to BLFS, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $86 million.
September 18, 2020
RegMed Investors’ (RMi) closing bell: follow the bouncing share pricing
September 18, 2020
RegMed Investors’ (RMi) pre-open: a sideline day to sit-out and watch for some sector turbulence
September 17, 2020
RegMed Investors’ (RMi) closing bell: the sector got thinned with the prevailing downside trade winds
September 17, 2020
RegMed Investors’ (RMi) pre-open: short-term trading ranges, safe or sorry?
September 16, 2020
RegMed Investors’ (RMi) closing bell: the sector’s latest ups and growing downs
September 16, 2020
RegMed Investors’ (RMi) pre-open: don’t chase pricing, follow fundamentals
September 15, 2020
RegMed Investors’ (RMi) closing bell: yippee-yi-yo-ki-yay
September 15, 2020
Q2/20 Earnings - (LPS - loss-per-share) Results
© 2020 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
